Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab with or without domvanalimab versus platinum-doublet chemotherapy in first-line PD-L1-positive advanced non-small cell lung cancer
2020-003562-39Phase 3Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of zimberelimab and domvanalimab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Arcus Biosciences. Primary endpoint: Progression-free survival. Started May 2021; status: completed.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003562-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003562-39.